Hypothalamic-pituitary-adrenal axis function in fibromyalgia and chronic fatigue syndrome

Endocrinologist

Volumn 12, Issue 6, 2002, Pages 513-524

  Adler, Gail K ^a   Manfredsdottir, Valdis F ^a   Rackow, Rachel M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; DEXFENFLURAMINE; GLUCOCORTICOID; HYDROCORTISONE; PRASTERONE; PREDNISONE;

ADRENAL INSUFFICIENCY; AUTONOMIC DYSFUNCTION; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; CORTICOTROPIN RELEASE; CORTICOTROPIN TEST; DRUG EFFICACY; FIBROMYALGIA; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NEUROENDOCRINE DISEASE; PREVALENCE; REVIEW; STEROID THERAPY; STRESS; SYMPTOMATOLOGY;

EID: 0036847883     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019616-200211000-00008     Document Type: Review

References (98)

1. Buskila D, Press J: Neuroendocrine mechanisms in fibromyalgiachronic fatigue. Best Pract Res Clin Rheumatol 2001; 15: 747-58.
2. Goldenberg DL: Fibromyalgia syndrome a decade later: What have we learned? Arch Intern Med 1999; 159: 777-785.
3. Bradley LA, McKendree-Smith NL, Alarcon GS: Pain complaints in patients with fibromyalgia versus chronic fatigue syndrome. Curr Rev Pain 2000; 4: 148-57.
4. Miller WL, Tyrrell JB: The Adrenal Cortex. In: Felig P, Baxter JD, Frohman LA, eds. Endocrinology and Metabolism. New York: McGraw-Hill; 1995: 555-711.
5. Singh A, Petrides JS, Gold PW, et al.: Differential hypothalamic-pituitary-adrenal axis reactivity to psychological and physical stress. J Clin Endocrinol Metab 1999; 84: 1944-8.
6. Wittert GA, Livesey JH, Espiner EA, et al.: Adaptation of the hypothalamopituitary adrenal axis to chronic exercise stress in humans. Med Sci Sports Exerc 1996; 28: 1015-19.
7. Kirschbaum C, Kudielka BM, Gaab J, et al.: Impact of gender, menstrual cycle phase, and oral contraceptives on the activity of the hypothalamus-pituitary-adrenal axis. Psychosom Med 1999; 61: 154-62.
8. Magiakou MA, Chrousos GP: Corticosteroid therapy, nonendocrine disease, and corticosteroid withdrawal. Curr Ther Endocrinol Metab 1994; 5: 120-4.
9. Bronnegard M, Werner S, Gustafsson JA: Primary cortisol resistance associated with a thermolabile glucocorticoid receptor in a patient with fatigue as the only symptom. J Clin Invest 1986; 78: 1270-8.
10. Chrousos GP, Detera-Wadleigh SD, Karl M: Syndromes of glucocorticoid resistance. Ann Intern Med 1993; 119: 1113-24.
11. Torpy DJ, Bachmann AW, Grice JE, et al.: Familial corticosteroidbinding globulin deficiency due to a novel null mutation: Association with fatigue and relative hypotension. J Clin Endocrinol Metab 2001; 86: 3692-700.
12. Plihal W, Krug R, Pietrowsky R, et al.: Corticosteroid receptor mediated effects on mood in humans. Psychoneuroendocrinology 1996; 21: 515-23.
13. Whitcomb JE, Findling JW, Raff H, et al.: Randomized trial of oral hydrocortisone and its effect on emergency physicians during night duty. WMJ 2000; 99: 37-41, 46.
14. Dodd SL, Herb RA, Powers SK: Caffeine and exercise performance. An update. Sports Med 1993; 15: 14-23.
15. Graham TE, Spriet LL: Performance and metabolic responses to a high caffeine dose during prolonged exercise. J Appl Physiol 1991; 71: 2292-8.
16. Jackman M, Wendling P, Friars D, et al.: Metabolic catecholamine, and endurance responses to caffeine during intense exercise. J Appl Physiol 1996; 81: 1658-63.
17. Adler GK: Exercise and fatigue-is neuroendocrinology an important factor? J Clin Endocrinol Metab 2000; 85: 2167-9.
18. Laurent D, Schneider KE, Prusaczyk WK, et al.: Effects of caffeine on muscle glycogen utilization and the neuroendocrine axis during exercise. J Clin Endocrinol Metab 2000; 85: 2170-5.
19. Lariviere WR, Melzack R: The role of corticotropin-releasing factor in pain and analgesia. Pain 2000; 84: 1-12.
20. Stratakis CA, Chrousos GP: Neuroendocrinology and pathophysiology of the stress system. Ann N Y Acad Sci 1995; 771: 1-18.
21. Pacak K, Palkovits M, Kopin IJ, et al.: Stress-induced norepinephrine release in the hypothalamic paraventricular nucleus and pituitaryadrenocortical and sympathoadrenal activity: In vivo microdialysis studies. Front Neuroendocrinol 1995; 16: 89-150.
22. Bandler R, Shipley MT: Columnar organization in the midbrain periaqueductal gray: Modules for emotional expression? Trends Neurosci 1994; 17: 379-89.
23. Fields HL, Heinricher MM, Mason P: Neurotransmitters in nociceptive modulatory circuits. Annu Rev Neurosci 1991; 14: 219-45.
24. Lovick TA: Integrated activity of cardiovascular and pain regulatory systems: Role in adaptive behavioural responses. Prog Neurobiol 1993; 40: 631-44.
25. Randich A: Interactions between cardiovascular and pain regulatory systems. In: Kunos G, Ciriello J, eds. Central Neural Mechanisms in Cardiovascular Regulation. Boston: Birkhauser. 1992: 297-320.
26. Fukuda K, Straus SE, Hickie I, et al.: The chronic fatigue syndrome: A comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994; 121: 953-9.
27. Freeman R, Komaroff AL: Does the chronic fatigue syndrome involve the autonomic nervous system? Am J Med 1997; 102: 357-64.
28. Jason LA, Richman JA, Rademaker AW, et al.: A community-based study of chronic fatigue syndrome. Arch Intern Med 1999; 159: 2129-37.
29. Demitrack MA, Dale JK, Straus SE, et al.: Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991; 73: 1224-34.
30. Scott LV, Dinan TG: Urinary free cortisol excretion in chronic fatigue syndrome, major depression and in healthy volunteers. J Affect Disord 1998; 47: 49-54.
31. Cleare AJ, Miell J, Heap E, et al.: Hypothalamo-pituitary-adrenal axis dysfunction in chronic fatigue syndrome, and the effects of low-dose hydrocortisone therapy. J Clin Endocrinol Metab 2001; 86: 3545-54.
32. Cleare AJ, Blair D, Chambers S, et al.: Urinary free cortisol in chronic fatigue syndrome. Am J Psychiatry 2001; 158: 641-3.
33. Korszun A, Sackett-Lundeen L, Papadopoulos E, et al.: Melatonin levels in women with fibromyalgia and chronic fatigue syndrome. J Rheumatol 1999; 26: 2675-80.
34. Dinan TG, Majeed T, Lavelle E, et al.: Blunted serotonin-mediated activation of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome. Psychoneuroendocrinology 1997; 22: 261-7.
35. Altemus M, Dale JK, Michelson D, et al.: Abnormalities in response to vasopressin infusion in chronic fatigue syndrome. Psychoneuroendocrinology 2001; 26: 175-88.
36. Scott LV, Burnett F, Medbak S, et al.: Naloxone-mediated activation of the hypothalamic-pituitary-adrenal axis in chronic fatigue syndrome. Psychol Med 1998; 28: 285-93.
37. Scott LV, Medbak S, Dinan TG: Blunted adrenocorticotropin and cortisol responses to corticotropin-releasing hormone stimulation in chronic fatigue syndrome. Acta Psychiatr Scand 1998; 97: 450-7.
38. Strickland P, Morriss R, Wearden A, et al.: A comparison of salivary cortisol in chronic fatigue syndrome, community depression and healthy controls. J Affect Disord 1998; 47: 191-4.
39. Wood B, Wessely S, Papadopoulos A, et al.: Salivary cortisol profiles in chronic fatigue syndrome. Neuropsychobiology 1998; 37: 1-4.
40. Young AH, Sharpe M, Clements A, et al.: Basal activity of the hypothalamic-pituitary-adrenal axis in patients with the chronic fatigue syndrome (neurasthenia). Biol Psychiatry 1998; 43: 236-7.
41. Vercoulen JH, Bazelmans E, Swanink CM, et al.: Physical activity in chronic fatigue syndrome: Assessment and its role in fatigue. J Psychiatr Res 1997; 31: 661-73.
42. Bazelmans E, Bleijenberg G, van der Meer JW, et al.: Is physical deconditioning a perpetuating factor in chronic fatigue syndrome? A controlled study on maximal exercise performance and relations with fatigue, impairment and physical activity. Psychol Med 2001; 31: 107-14.
43. Bearn J, Allain T, Coskeran P, et al.: Neuroendocrine responses to d-fenfluramine and insulin-induced hypoglycemia in chronic fatigue syndrome. Biol Psychiatry 1995; 37: 245-52.
44. Moorkens G, Berwaerts J, Wynants H, et al.: Characterization of pituitary function with emphasis on GH secretion in the chronic fatigue syndrome. Clin Endocrinol (Oxf) 2000; 53: 99-106.
45. Ottenweller JE, Sisto SA, McCarty RC, et al.: Hormonal responses to exercise in chronic fatigue syndrome. Neuropsychobiology 2001; 43: 34-41.
46. Kavelaars A, Kuis W, Knook L, et al.: Disturbed neuroendocrineimmune interactions in chronic fatigue syndrome. J Clin Endocrinol Metab 2000; 85: 692-6.
47. Scott LV, Medbak S, Dinan TG: Desmopressin augments pituitaryadrenal responsivity to corticotropin-releasing hormone in subjects with chronic fatigue syndrome and in healthy volunteers. Biol Psychiatry 1999; 45: 1447-54.
48. Cleare AJ, Bearn J, Allain T, et al.: Contrasting neuroendocrine responses in depression and chronic fatigue syndrome. J Affect Disord 1995; 34: 283-9.
49. Yatham LN, Morehouse RL, Chisholm BT, et al.: Neuroendocrine assessment of serotonin (5-HT) function in chronic fatigue syndrome. Can J Psychiatry 1995; 40: 93-6.
50. Scott LV, Medbak S, Dinan TG: The low dose ACTH test in chronic fatigue syndrome and in health. Clin Endocrinol (Oxf) 1998; 48: 733-7.
51. De Becker P, De Meirleir K, Joos E, et al.: Dehydroepiandrosterone (DHEA) response to i.v. ACTH in patients with chronic fatigue syndrome. Horm Metab Res 1999; 31: 18-21.
52. Hudson M, Cleare AJ: The 1microg short Synacthen test in chronic fatigue syndrome. Clin Endocrinol (Oxf) 1999; 51: 625-30.
53. Scott LV, Svec F, Dinan T: A preliminary study of dehydroepiandrosterone response to low-dose ACTH in chronic fatigue syndrome and in healthy subjects. Psychiatry Res 2000; 97: 21-8.
54. Cleare AJ, Heap E, Malhi GS, et al.: Low-dose hydrocortisone in chronic fatigue syndrome: A randomised crossover trial. Lancet 1999; 353(9151): 455-8.
55. McKenzie R, O'Fallon A, Dale J, et al.: Low-dose hydrocortisone for treatment of chronic fatigue syndrome: A randomized controlled trial. JAMA 1998; 280: 1061-6.
56. Wolfe F, Smythe HA, Yunus MB, et al.: The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160-72.
57. Wolfe F, Ross K, Anderson J, et al.: The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995; 38: 19-28.
58. Mikkelsson M, Latikka P, Kautiainen H, et al.: Muscle and bone pressure pain threshold and pain tolerance in fibromyalgia patients and controls. Arch Phys Med Rehabil 1992; 73: 814-8.
59. Granges G, Littlejohn G: Pressure pain threshold in pain-free subjects, in patients with chronic regional pain syndromes, and in patients with fibromyalgia syndrome. Arthritis Rheum 1993; 36: 642-6.
60. McDermid AJ, Rollman GB, McCain GA: Generalized hypervigilance in fibromyalgia: Evidence of perceptual amplification. Pain 1996; 66(2-3): 133-44.
61. Berglund B, Harju EL, Kosek E, et al.: Quantitative and qualitative perceptual analysis of cold dysesthesia and hyperalgesia in fibromyalgia. Pain 2002; 96(1-2): 177-87.
62. Weigent DA, Bradley LA, Blalock JE, et al.: Current concepts in the pathophysiology of abnormal pain perception in fibromyalgia. Am J Med Sci 1998; 315: 405-12.
63. Clauw DJ, Chrousos GP: Chronic pain and fatigue syndromes: Overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation 1997; 4: 134-53.
64. Park JH, Niermann KJ, Olsen N: Evidence for metabolic abnormalities in the muscles of patients with fibromyalgia. Curr Rheumatol Rep 2000; 2: 131-40.
65. Crofford LJ, Pillemer SR, Kalogeras KT, et al.: Hypothalamicpituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 1994; 37: 1583-92.
66. Lentjes EG, Griep EN, Boersma JW, et al.: Glucocorticoid receptors, fibromyalgia and low back pain. Psychoneuroendocrinology 1997; 22: 603-14.
67. Adler GK, Kinsley BT, Hurwitz S, et al.: Reducued hypothalamicpituitary and sympathoadrenal responses to hypoglycemia in women with fibromvalgia syndrome. Am I Med 1999; 106: 534-43.
68. Maes M, Lin A, Bonaccorso S, et al.: Increased 24-hour urinary cortisol excretion in patients with post-traumatic stress disorder and patients with major depression, but not in patients with fibromyalgia. Acta Psychiatr Scand 1998; 98: 328-35.
69. Klerman EB, Goldenberg DL, Brown EN, et al.: Circadian rhythms of women with fibromyalgia. J Clin Endocrinol Metab 2001; 86: 1034-9.
70. Kirnap M, Colak R, Eser C, et al.: A comparison between low-dose (1 microg), standard-dose (250 microg) ACTH stimulation tests and insulin tolerance test in the evaluation of hypothalamo-pituitaryadrenal axis in primary fibromyalgia syndrome. Clin Endocrinol (Oxf) 2001; 55: 455-9.
71. Griep EN, Boersma JW, de Kloet ER: Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome. J Rheumatol 1993; 20: 469-74.
72. Torpy DJ, Papanicolaou DA, Lotsikas AJ, et al.: Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6: A pilot study in fibromyalgia. Arthritis Rheum 2000; 43: 872-80.
73. van Denderen JC, Boersma JW, Zeinstra P, et al.: Physiological effects of exhaustive physical exercise in primary fibromyalgia syndrome (PFS): Is PFS a disorder of neuroendocrine reactivity? Scand J Rheumatol 1992; 21: 35-7.
74. Griep EN, Boersma JW, de Kloet ER: Evidence for neuroendocrine disturbance following physical exercise in primary fibromyalgia syndrome. J Musculoskeltal Pain 1993; 1: 217-22.
75. Gursel Y, Ergin S, Ulus Y, et al.: Hormonal responses to exercise stress test in patients with fibromyalgia syndrome. Clin Rheumatol 2001; 20: 401-5.
76. Griep EN, Boersma JW, Lentjes EG, et al.: Function of the hypothalamic-pituitary-adrenal axis in patients with fibromyalgia and low back pain. J Rheumatol 1998; 25: 1374-81.
77. Maliszewski AM, Goldenberg DL, Hurwitz S, et al.: Regulation of the renin-angiotensin-aldosterone system in fibromyalgia. J Rheumatol 2002, in press.
78. Riedel W, Layka H, Neeck G: Secretory pattern of GH, TSH, thyroid hormones, ACTH, cortisol, FSH, and LH in patients with fibromyalgia syndrome following systemic injection of the relevant hypothalamic-releasing hormones. Z Rheumatol 1998; 57 Suppl 2: 81-7.
79. Clark S, Tindall E, Bennett RM: A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis. J Rheumatol 1985; 12: 980-3.
80. Bagge E, Bengtsson BA, Carlsson L, et al.: Low growth hormone secretion in patients with fibromyalgia-a preliminary report on 10 patients and 10 controls. J Rheumatol 1998; 25: 145-8.
81. Leal-Cerro A, Povedano J, Astorga R, et al.: The growth hormone (GH)-releasing hormone-GH-insulin-like growth factor-1 axis in patients with fibromyalgia syndrome. J Clin Endocrinol Metab 1999; 84: 3378-81.
82. Landis CA, Lentz MJ, Rothermel J, et al.: Decreased nocturnal levels of prolactin and growth hormone in women with fibromyalgia. J Clin Endocrinol Metab 2001; 86: 1672-8.
83. Neeck G, Riedel W: Thyroid function in patients with fibrornyalgia syndrome. J Rheumatol 1992; 19: 1120-1122.
84. Martinez-Lavin M, Hermosillo AG, Mendoza C, et al.: Orthostatic sympathetic derangement in subjects with fibromyalgia. J Rheumatol 1997; 24: 714-8.
85. Raj SR, Brouillard D, Simpson CS, et al.: Dysautonomia among patients with fibromyalgia: A noninvasive assessment. J Rheumatol 2000; 27: 2660-5.
86. Bou-Holaigah I, Calkins H, Flynn JA, et al.: Provocation of hypotension and pain during upright tilt table testing in adults with fibromyalgia. Clin Exp Rheumatol 1997; 15: 239-46.
87. Qiao ZG, Vaeroy H, Morkrid L: Electrodermal and microcirculatory activity in patients with fibromyalgia during baseline, acoustic stimulation and cold pressor tests. J Rheumatol 1991; 18: 1383-9.
88. Martinez-Lavin M, Hermosillo AG, Rosas M, et al.: Circadian studies of autonomic nervous balance in patients with fibromyalgia: A heart rate variability analysis. Arthritis Rheum 1998; 41: 1966-71.
89. Allain TJ, Bearn JA, Coskeran P, et al.: Changes in growth hormone, insulin, insulinlike growth factors (IGFs), and IGF-binding protein-1 in chronic fatigue syndrome. Biol Psychiatry 1997; 41: 567-73.
90. Berwaerts J, Moorkens G, Abs R: Secretion of growth hormone in patients with chronic fatigue syndrome. Growth Horm IGF Res 1998; 8 Suppl B: 127-9.
91. Cleare AJ, Sookdeo SS, Jones J, et al.: Integrity of the growth hormone/insulin-like growth factor system is maintained in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 2000; 85: 1433-9.
92. Bou-Holaigah I, Rowe PC, Kan J, et al.: The relationship between neurally mediated hypotension and the chronic fatigue syndrome. JAMA 1995; 274: 961-7.
93. LaManca JJ, Peckerman A, Sisto SA, et al.: Cardiovascular responses of women with chronic fatigue syndrome to stressful cognitive testing before and after strenuous exercise. Psychosom Med 2001; 63: 756-64.
94. Cryer PE: Hypoglycemia-associated autonomic failure in diabetes. Am J Physiol Endocrinol Metab 2001; 281: E1115-21.
95. Segel SA, Fanelli CG, Dence CS, et al.: Blood-to-brain glucose transport, cerebral glucose metabolism, and cerebral blood flow are not increased after hypoglycemia. Diabetes 2001; 50: 1911-7.
96. Davis SN, Shavers C, Costa F, et al.: Role of cortisol in the pathogenesis of deficient counterregulation after antecedent hypoglycemia in normal humans. J Clin Invest 1996; 98: 680-91.
97. Galassetti P, Mann S, Tate D, et al.: Effects of antecedent prolonged exercise on subsequent counterregulatory responses to hypoglycemia. Am J Physiol Endocrinol Metab 2001; 280: E908-17.
98. Whiting P, Bagnall AM, Sowden AJ, et al.: Interventions for the treatment and management of chronic fatigue syndrome: A systematic review. JAMA 2001; 286: 1360-68.